Design Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results beat consensus on both top and bottom lines: net loss of $20.2M was narrower than the expected $21.4M, and GAAP EPS of -$0.32 exceeded the -$0.345 mean estimate. The company maintained a strong liquidity position with $207.4M in cash and securities, supporting clinical advancements in DT-216P2 (Friedreich ataxia) and the initiation of DT-818 (DM1) dosing. However, data for the FECD program (DT-168) is delayed to 2027 due to supply chain issues.